Open AccessEfficacy and safety of Chuankezhi injection in patients with chronic obstructive pulmonary disease
Author(s) -
Zhenhua Zhou,
Weipeng Zheng,
Ting Liang,
Qian Yan,
Chaoyuan Zhang,
Hui-Ting Huang,
Xiaohong Liu,
Xiaohan Ye
Publication year - 2020
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000018620
Subject(s) - medicine , copd , pulmonary disease , protocol (science) , inclusion and exclusion criteria , randomized controlled trial , intensive care medicine , medline , clinical trial , meta analysis , physical therapy , alternative medicine , pathology , political science , law
Background: Chuankezhi injection (CKZ) is gaining increasing popularity for chronic obstructive pulmonary disease (COPD) treatment, yet their comparative effectiveness and safety remain unclear. Therefore, we will provide a protocol to assess the efficacy and safety of CKZ for COPD. Methods: From now until June 2020, we will conduct a comprehensive and systematic literature search in 4 Chinese and 4 English databases, and the use of CKZ in the treatment of COPD will be included in randomized controlled trials, as well as all the treatment of stable COPD during the treatment of all CKZ. The risk assessment of the bias tool in Cochrane 5.1.0 will be combined with the quality of the trial. The 2 investigators will independently perform quality assessments and data extractions for the included studies in strict accordance with inclusion and exclusion criteria and perform the meta-analysis with Stata 15 software (version 15.0, StataCorp, College Station, TX). Results: Further evidence of CKZ treatment for COPD will be provided by this study. Conclusion: The efficacy and safety assessment of CKZ for COPD will be supported by this protocol. PROSPERO registration number: ROSPERO CRD 42019134133.